Crossmark

Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease

Crossref DOI link: https://doi.org/10.1038/s41593-018-0332-9

Published Online: 2019-02-11

Published Print: 2019-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fang, Evandro F. https://orcid.org/0000-0003-0355-7202
Hou, Yujun

Palikaras, Konstantinos

Adriaanse, Bryan A.

Kerr, Jesse S.

Yang, Beimeng

Lautrup, Sofie

Hasan-Olive, Md Mahdi

Caponio, Domenica https://orcid.org/0000-0002-3827-8943
Dan, Xiuli

Rocktäschel, Paula

Croteau, Deborah L.

Akbari, Mansour

Greig, Nigel H.

Fladby, Tormod

Nilsen, Hilde

Cader, M. Zameel

Mattson, Mark P.

Tavernarakis, Nektarios https://orcid.org/0000-0002-5253-1466
Bohr, Vilhelm A. https://orcid.org/0000-0003-4823-6429
License Information

Text and Data Mining valid from 2019-02-11
More Information

Article History

Received: 12 March 2018

Accepted: 17 December 2018

First Online: 11 February 2019

Competing interests

: E.F.F., V.A.B., and H.N. have Cooperative Research and Development Agreement (CRADA) arrangements with ChromaDex. V.A.B. also has a CRADA with Elysium Health.